Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000819207 | SCV000959854 | pathogenic | Hereditary nonpolyposis colorectal neoplasms | 2018-09-19 | criteria provided, single submitter | clinical testing | This variant is a gross deletion of the genomic region encompassing exons 2-9 of the EPCAM gene. The 5' boundary is likely confined to intron 1. The 3' end of this event is unknown as it extends through the termination codon beyond the assayed region for this gene and may encompass additional genes. While this deletion is not anticipated to result in nonsense mediated decay, it is expected to create a truncated protein product or disrupt mRNA translation. A similar gross deletion of exons 2-9 of the EPCAM gene has been reported in an individual with a personal or family history of Lynch syndrome-related cancer (PMID: 25980754). Additionally, several smaller deletions encompassed within this larger deletion have been reported in individuals affected with Lynch syndrome (PMID: 23454724, 21309036, 21227399, 20864635, 22243433). Deletions involving the 3’ region of the EPCAM gene (minimally, exon 9) are known to cause Lynch syndrome. These deletions lead to transcriptional read-through from the EPCAM promoter into the adjacent MSH2 gene, resulting in hypermethylation of the MSH2 promoter and silencing of MSH2 expression (PMID: 19098912, 19177550, 21309036). For these reasons, this variant has been classified as Pathogenic. |